Targeting receptor for advanced glycation end products (RAGE) expression induces apoptosis and inhibits prostate tumor growth

Biochemical and Biophysical Research Communications

Volumn 417, Issue 4, 2012, Pages 1133-1138

  Elangovan, Indira ^a   Thirugnanam, Sivasakthivel ^a   Chen, Aoshuang ^a   Zheng, Guoxing ^a   Bosland, Maarten C ^b   Kajdacsy Balla, André ^b   Gnanasekar, Munirathinam ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Apoptosis and prostate cancer; HMGB1; RAGE; RNAi

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CASPASE 3; CASPASE 8; DEATH RECEPTOR 4; DEATH RECEPTOR 5; HIGH MOBILITY GROUP B1 PROTEIN; PROSTATE SPECIFIC ANTIGEN; RNA; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; EXPERIMENTAL NEOPLASM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HMGB1 PROTEIN; HUMANS; LIGANDS; MALE; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84856218685     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.12.060     Document Type: Article

References (30)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths, CA. Cancer J. Clin. 2011, 61:212-236.
2. Schmidt A.M., Hori O., Cao R., Yan S.D., Brett J., Wautier J.L., Ogawa S., Kuwabara K., Matsumoto M., Stern D. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996, 45(Suppl 3):S77-80.
3. Leclerc E., Sturchler E., Vetter S.W., Heizmann C.W. Crosstalk between calcium, amyloid beta and the receptor for advanced glycation end products in Alzheimer's disease. Rev. Neurosci. 2009, 20:95-110.
4. Leclerc E., Fritz G., Vetter S.W., Heizmann C.W. Binding of S100 proteins to RAGE: an update. Biochim. Biophys. Acta 2009, 1793:993-1007.
5. Hori O., Brett J., Slattery T., Cao R., Zhang J., Chen J.X., Nagashima M., Lundh E.R., Vijay S., Nitecki D., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 1995, 270:25752-25761.
6. Lander H.M., Tauras J.M., Ogiste J.S., Hori O., Moss R.A., Schmidt A.M. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 1997, 272:17810-17814.
7. Huttunen H.J., Fages C., Rauvala H. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J. Biol. Chem. 1999, 274:19919-19924.
8. Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., Tanji N., Lu Y., Lalla E., Fu C., Hofmann M.A., Kislinger T., Ingram M., Lu A., Tanaka H., Hori O., Ogawa S., Stern D.M., Schmidt A.M. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-360.
9. Huang J.S., Guh J.Y., Chen H.C., Hung W.C., Lai Y.H., Chuang L.Y. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J. Cell. Biochem. 2001, 81:102-113.
10. Li J., Qu X., Schmidt A.M. Sp1-binding elements in the promoter of RAGE are essential for amphoterin-mediated gene expression in cultured neuroblastoma cells. J. Biol. Chem. 1998, 273:30870-30878.
11. Kuniyasu H., Oue N., Wakikawa A., Shigeishi H., Matsutani N., Kuraoka K., Ito R., Yokozaki H., Yasui W. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J. Pathol. 2002, 196:163-170.
12. Sims G.P., Rowe D.C., Rietdijk S.T., Herbst R., Coyle A.J. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 2010, 28:367-388.
13. Choi J., Lee M.K., Oh K.H., Kim Y.S., Choi H.Y., Baek S.K., Jung K.Y., Woo J.S., Lee S.H., Kwon S.Y. Interaction effect between the receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line. Tumori 2011, 97:196-202.
14. Hsieh H.L., Schafer B.W., Sasaki N., Heizmann C.W. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem. Biophys. Res. Commun. 2003, 307:375-381.
15. Kuniyasu H., Chihara Y., Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int. J. Cancer 2003, 104:722-727.
16. Kuniyasu H., Chihara Y., Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol. Rep. 2003, 10:445.
17. Ishiguro H., Nakaigawa N., Miyoshi Y., Fujinami K., Kubota Y., Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate 2005, 64:92-100.
18. Kang R., Tang D., Schapiro N.E., Livesey K.M., Farkas A., Loughran P., Bierhaus A., Lotze M.T., Zeh H.J. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ. 2010, 17:666-676.
19. Landesberg R., Woo V., Huang L., Cozin M., Lu Y., Bailey C., Qu W., Pulse C., Schmidt A.M. The expression of the receptor for glycation endproducts (RAGE) in oral squamous cell carcinomas. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2008, 105:617-624.
20. Gebhardt C., Riehl A., Durchdewald M., Nemeth J., Furstenberger G., Muller-Decker K., Enk A., Arnold B., Bierhaus A., Nawroth P.P., Hess J., Angel P. RAGE signaling sustains inflammation and promotes tumor development. J. Exp. Med. 2008, 205:275-285.
21. Eichmüller S., Usener D., Jochim A., Schadendorf D. MRNA expression of tumor-associated antigens in melanoma tissues and cell lines. Exp. Dermatol. 2002, 11:292-301.
22. Bartling B., Demling N., Silber R.E., Simm A. Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced glycation end-products. Am. J. Respir. Cell Mol. Biol. 2006, 34:83-91.
23. DiNorcia J., Moroziewicz D.N., Ippagunta N., Lee M.K., Foster M., Rotterdam H.Z., Bao F., Zhou Y.S., Yan S.F., Emond J., Schmidt A.M., Allendorf J.D. RAGE signaling significantly impacts tumorigenesis and hepatic tumor growth in murine models of colorectal carcinoma. J. Gastrointest. Surg. 2010, 14:1680-1690.
24. J. Dinorcia, M.K. Lee, D.N. Moroziewicz, M. Winner, P. Suman, F. Bao, H.E. Remotti, Y.S. Zou, S.F. Yan, W. Qiu, G.H. Su, A.M. Schmidt, J.D. Allendorf, RAGE Gene Deletion Inhibits the Development and Progression of Ductal Neoplasia and Prolongs Survival in a Murine Model of Pancreatic Cancer, J. Gastrointest. Surg. (2011).
25. Gnanasekar M., Thirugnanam S., Ramaswamy K. Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int. J. Oncol. 2009, 34:425-431.
26. Bassi R., Giussani P., Anelli V., Colleoni T., Pedrazzi M., Patrone M., Viani P., Sparatore B., Melloni E., Riboni L. HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration. J. Neurooncol. 2008, 87:23-33.
27. Wang D., Fung J.N., Tuo Y., Hu L., Chen C. TWEAK/Fn14 promotes apoptosis of human endometrial cancer cells via caspase pathway. Cancer Lett. 2010, 294:91-100.
28. Ban Y., Wang M.C., Watt K.W., Loor R., Chu T.M. The proteolytic activity of human prostate-specific antigen. Biochem. Biophys. Res. Commun. 1984, 123:482-488.
29. Lilja H., Ulmert D., Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 2008, 8:268-278.
30. Williams S.A., Jelinek C.A., Litvinov I., Cotter R.J., Isaacs J.T., Denmeade S.R. Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. The Prostate 2011, 71:1595-1607.